KR100621287B1 - 신경 펩타이드 ｙ 수용체에 대한 리간드로서의 퀴놀린유도체 - Google Patents
신경 펩타이드 ｙ 수용체에 대한 리간드로서의 퀴놀린유도체 Download PDFInfo
- Publication number
- KR100621287B1 KR100621287B1 KR1020037015121A KR20037015121A KR100621287B1 KR 100621287 B1 KR100621287 B1 KR 100621287B1 KR 1020037015121 A KR1020037015121 A KR 1020037015121A KR 20037015121 A KR20037015121 A KR 20037015121A KR 100621287 B1 KR100621287 B1 KR 100621287B1
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- pyrrolidin
- quinolin
- quinoline
- benzonitrile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *CCC(*)(*)CCCCCc1c(cc(*)c(*)c2)c2nc(*)c1 Chemical compound *CCC(*)(*)CCCCCc1c(cc(*)c(*)c2)c2nc(*)c1 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01112370.0 | 2001-05-21 | ||
| EP01112370 | 2001-05-21 | ||
| PCT/EP2002/005120 WO2002094789A1 (en) | 2001-05-21 | 2002-05-08 | Quinoline derivatives as ligands for the neuropeptide y receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20030096416A KR20030096416A (ko) | 2003-12-24 |
| KR100621287B1 true KR100621287B1 (ko) | 2006-09-13 |
Family
ID=8177497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020037015121A Expired - Fee Related KR100621287B1 (ko) | 2001-05-21 | 2002-05-08 | 신경 펩타이드 ｙ 수용체에 대한 리간드로서의 퀴놀린유도체 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US6818767B2 (enExample) |
| EP (1) | EP1395564B1 (enExample) |
| JP (1) | JP3715280B2 (enExample) |
| KR (1) | KR100621287B1 (enExample) |
| CN (1) | CN100376557C (enExample) |
| AR (1) | AR035979A1 (enExample) |
| AT (1) | ATE387428T1 (enExample) |
| AU (1) | AU2002338896B2 (enExample) |
| BR (1) | BR0209957A (enExample) |
| CA (1) | CA2446324A1 (enExample) |
| DE (1) | DE60225274T2 (enExample) |
| ES (1) | ES2300478T3 (enExample) |
| GT (1) | GT200200090A (enExample) |
| MX (1) | MXPA03010565A (enExample) |
| PA (1) | PA8545301A1 (enExample) |
| PE (1) | PE20021155A1 (enExample) |
| UY (1) | UY27300A1 (enExample) |
| WO (1) | WO2002094789A1 (enExample) |
| ZA (1) | ZA200308783B (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6900226B2 (en) * | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
| JP2005519876A (ja) * | 2001-11-27 | 2005-07-07 | メルク エンド カムパニー インコーポレーテッド | ２−アミノキノリン化合物 |
| MXPA04007502A (es) | 2002-02-04 | 2004-11-10 | Hoffmann La Roche | Derivados de quinolina como antagonistas de neuropeptido y (npy). |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| RU2296757C2 (ru) | 2002-07-05 | 2007-04-10 | Ф.Хоффманн-Ля Рош Аг | Производные хиназолина |
| BR0313278A (pt) | 2002-08-07 | 2005-07-05 | Hoffmann La Roche | Compostos, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo e sua utilização, método para o tratamento e profilaxia de enfermidades e obesidade e utilização dos compostos |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| JP2006519846A (ja) * | 2003-03-10 | 2006-08-31 | シェーリング コーポレイション | 複素環式キナーゼインヒビター：使用および合成の方法 |
| JP4765627B2 (ja) | 2003-09-22 | 2011-09-07 | Ｍｓｄ株式会社 | 新規ピペリジン誘導体 |
| JP2007510745A (ja) | 2003-11-10 | 2007-04-26 | シンタ ファーマシューティカルズ コーポレーション | 縮合複素環式化合物 |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| US20060183763A1 (en) * | 2004-12-31 | 2006-08-17 | Pfizer Inc | Novel pyrrolidyl derivatives of heteroaromatic compounds |
| RU2417985C2 (ru) | 2005-05-30 | 2011-05-10 | Баниу Фармасьютикал Ко., Лтд. | Новые производные пиперидина |
| WO2007018248A1 (ja) | 2005-08-10 | 2007-02-15 | Banyu Pharmaceutical Co., Ltd. | ピリドン化合物 |
| CA2619770A1 (en) | 2005-08-24 | 2007-03-01 | Banyu Pharmaceutical Co., Ltd. | Phenylpyridone derivative |
| US20090264426A1 (en) | 2005-09-07 | 2009-10-22 | Shunji Sakuraba | Bicyclic aromatic substituted pyridone derivative |
| EP1944301A4 (en) | 2005-10-27 | 2012-01-04 | Msd Kk | NEW BENZOXATHIIN DERIVATIVES |
| US8158791B2 (en) | 2005-11-10 | 2012-04-17 | Msd K.K. | Aza-substituted spiro derivatives |
| WO2008020302A2 (en) * | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
| US20090247560A1 (en) | 2006-09-28 | 2009-10-01 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
| JP5319518B2 (ja) | 2007-04-02 | 2013-10-16 | Ｍｓｄ株式会社 | インドールジオン誘導体 |
| WO2008141077A1 (en) * | 2007-05-10 | 2008-11-20 | Janssen Pharmaceutica N.V. | Process for the preparation of tetrahydroquinolinyl, benzoxazine and benzothiazine derivatives |
| PT2182950T (pt) | 2007-05-17 | 2017-09-11 | Helperby Therapeutics Ltd | Uso de compostos 4-(pirrolidin-1-il)quinolina para eliminação de microrganismos clinicamente latentes |
| WO2008150940A1 (en) * | 2007-06-01 | 2008-12-11 | E. I. Du Pont De Nemours And Company | Chrysenes for green luminescent applications |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| US8034782B2 (en) | 2008-07-16 | 2011-10-11 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| SI2220076T1 (sl) * | 2007-11-15 | 2012-05-31 | Gilead Sciences Inc | Inhibitorji replikacije virusa humane imunske pomankljivosti |
| KR20100097156A (ko) | 2007-11-16 | 2010-09-02 | 베링거 인겔하임 인터내셔날 게엠베하 | 사람 면역결핍 바이러스 복제의 억제제 |
| US20110015181A1 (en) | 2008-03-06 | 2011-01-20 | Makoto Ando | Alkylaminopyridine derivative |
| US20110015198A1 (en) | 2008-03-28 | 2011-01-20 | Banyu Pharmaceutical Co., Inc. | Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism |
| EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| CA2727914A1 (en) | 2008-06-19 | 2009-12-23 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diaryl ketoxime derivative technical field |
| AU2009277736A1 (en) | 2008-07-30 | 2010-02-04 | Banyu Pharmaceutical Co., Ltd. | (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
| US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| PH12013501686A1 (en) | 2011-02-25 | 2017-10-25 | Merck Sharp & Dohme | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| CA2880901A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| RU2015140066A (ru) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
| CN105764916B (zh) | 2013-06-05 | 2021-05-18 | 博士医疗爱尔兰有限公司 | 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法 |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| SG11202000248UA (en) | 2017-07-14 | 2020-02-27 | Innate Tumor Immunity Inc | Nlrp3 modulators |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU43730A1 (enExample) * | 1962-06-14 | 1963-07-13 | ||
| US3272824A (en) * | 1962-12-06 | 1966-09-13 | Norwich Pharma Co | 4-amino-6, 7-di(lower) alkoxyquinolines |
| US3812127A (en) * | 1966-10-31 | 1974-05-21 | Pfizer | 4-(quinolin-4-yl)piperazine-1-carboxylic acid esters |
| US4035367A (en) * | 1974-09-09 | 1977-07-12 | Sandoz, Inc. | Hydroxyalkyl-substituted-amino-quinolines |
| CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| CA1328881C (en) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
| CA1270837A (en) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
| CA2035917C (en) | 1990-02-13 | 2001-10-02 | John L. Krstenansky | Stabilized sulfonate, sulfate, phosphonate and phosphate derivatives of hirudin |
| US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
| DK0882717T3 (da) * | 1996-10-01 | 2010-12-13 | Kyowa Hakko Kirin Co Ltd | Nitrogenholdige heterocykliske forbindelser |
| US6004996A (en) | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
| US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
| DE69916288T2 (de) | 1998-08-14 | 2005-03-24 | F. Hoffmann-La Roche Ag | Lipasehemmer und chitosan enthaltende arzneimittel |
| ATE293970T1 (de) | 1998-08-14 | 2005-05-15 | Hoffmann La Roche | Lipasehemmer enthaltende pharmazeutische zusammensetzungen |
| WO2001034764A2 (en) * | 1999-11-08 | 2001-05-17 | Cytion S.A. | Apparatus and methods for positioning and analyzing biological membranous objects |
| US6900226B2 (en) * | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
-
2002
- 2002-05-08 JP JP2002591462A patent/JP3715280B2/ja not_active Expired - Fee Related
- 2002-05-08 MX MXPA03010565A patent/MXPA03010565A/es active IP Right Grant
- 2002-05-08 CN CNB028104013A patent/CN100376557C/zh not_active Expired - Fee Related
- 2002-05-08 CA CA002446324A patent/CA2446324A1/en not_active Abandoned
- 2002-05-08 DE DE60225274T patent/DE60225274T2/de not_active Expired - Fee Related
- 2002-05-08 ES ES02771639T patent/ES2300478T3/es not_active Expired - Lifetime
- 2002-05-08 AT AT02771639T patent/ATE387428T1/de not_active IP Right Cessation
- 2002-05-08 AU AU2002338896A patent/AU2002338896B2/en not_active Ceased
- 2002-05-08 EP EP02771639A patent/EP1395564B1/en not_active Expired - Lifetime
- 2002-05-08 BR BR0209957-8A patent/BR0209957A/pt not_active IP Right Cessation
- 2002-05-08 KR KR1020037015121A patent/KR100621287B1/ko not_active Expired - Fee Related
- 2002-05-08 WO PCT/EP2002/005120 patent/WO2002094789A1/en not_active Ceased
- 2002-05-16 PA PA20028545301A patent/PA8545301A1/es unknown
- 2002-05-17 AR ARP020101836A patent/AR035979A1/es not_active Application Discontinuation
- 2002-05-17 PE PE2002000425A patent/PE20021155A1/es not_active Application Discontinuation
- 2002-05-20 US US10/151,505 patent/US6818767B2/en not_active Expired - Fee Related
- 2002-05-20 GT GT200200090A patent/GT200200090A/es unknown
- 2002-05-21 UY UY27300A patent/UY27300A1/es not_active Application Discontinuation
-
2003
- 2003-11-11 ZA ZA200308783A patent/ZA200308783B/en unknown
-
2004
- 2004-05-24 US US10/852,509 patent/US20050049413A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2446324A1 (en) | 2002-11-28 |
| EP1395564A1 (en) | 2004-03-10 |
| PE20021155A1 (es) | 2002-12-17 |
| US20020198194A1 (en) | 2002-12-26 |
| ATE387428T1 (de) | 2008-03-15 |
| US6818767B2 (en) | 2004-11-16 |
| US20050049413A1 (en) | 2005-03-03 |
| GT200200090A (es) | 2003-06-19 |
| JP2004536066A (ja) | 2004-12-02 |
| WO2002094789A1 (en) | 2002-11-28 |
| JP3715280B2 (ja) | 2005-11-09 |
| EP1395564B1 (en) | 2008-02-27 |
| AU2002338896B2 (en) | 2006-04-27 |
| BR0209957A (pt) | 2004-03-30 |
| PA8545301A1 (es) | 2003-01-24 |
| DE60225274T2 (de) | 2009-03-26 |
| ZA200308783B (en) | 2005-02-11 |
| KR20030096416A (ko) | 2003-12-24 |
| MXPA03010565A (es) | 2004-03-02 |
| UY27300A1 (es) | 2002-11-29 |
| ES2300478T3 (es) | 2008-06-16 |
| AR035979A1 (es) | 2004-07-28 |
| DE60225274D1 (de) | 2008-04-10 |
| CN1522249A (zh) | 2004-08-18 |
| CN100376557C (zh) | 2008-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100621287B1 (ko) | 신경 펩타이드 ｙ 수용체에 대한 리간드로서의 퀴놀린유도체 | |
| RU2300531C2 (ru) | Хинолиновые производные в качестве антагонистов нейропептида y | |
| KR100621272B1 (ko) | 퀴놀린 및 퀴나졸린 유도체 | |
| KR100659428B1 (ko) | Ｎｐｙ 길항제로서의 퀴놀린 유도체 | |
| US8173639B2 (en) | Isoquinolinone derivatives as NK3 antagonists | |
| US6353010B1 (en) | Bicyclic aryl carboxamides and their therapeutic use | |
| CA2652852A1 (fr) | Derives d'urees de piperidine ou pyrrolidine, leur preparation et leur application en therapeutique | |
| JP2007505951A (ja) | Ｃｃｒ−５アンタゴニストとしてのキノリルアミド誘導体類 | |
| KR100611853B1 (ko) | 피리미딘 유도체 및 이의 신경펩타이드 ｙ 수용체리간드로서의 용도 | |
| KR100647932B1 (ko) | 퀴나졸린 유도체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20090831 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20090831 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |